Comparative Study between combination therapy Empagliflozin–Sitagliptin and Empagliflozin–Alogliptin in addition to Metformin assessing the hypoglycemic effect on patients diagnosed with malignancy and poorly controlled Type 2 diabetes mellitus as comorbidity. JOC [Internet]. 2025 Sep. 23 [cited 2026 Mar. 18];24(3):669-74. Available from: https://carcinogenesis.com/index.php/JOC/article/view/1025